Journal
ACTA DIABETOLOGICA
Volume 58, Issue 7, Pages 949-957Publisher
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s00592-021-01703-z
Keywords
Familial hypercholesterolemia; PCSK9 inhibitors; Pulse wave velocity; Innate immunity; Inflammatory profile; Cardiovascular risk
Categories
Funding
- Universita degli Studi di Catania within the CRUI-CARE Agreement
Ask authors/readers for more resources
This study aimed to evaluate the impact of PCSK9-i therapy on inflammatory biomarkers, pulse wave velocity, and atherosclerosis damage in FH subjects. The results showed that PCSK9-i therapy significantly reduced LDL-C levels, neutrophil count, and MHR, while also decreasing PWV. Additionally, there was a significant association between an increase in PWV and an increase in LDL-C, neutrophil count, and MHR.
Aims Subjects with familial hypercholesterolemia (FH) are characterized by an increased amount of low-density lipoprotein cholesterol (LDL-C) that promotes a continuous inflammatory stimulus. Our aim was to evaluate the effect of PCSK9-i on inflammatory biomarkers, neutrophil-to-lymphocyte ratio, monocyte-to-high-density lipoprotein ratio (MHR), and on early atherosclerosis damage analyzed by pulse wave velocity (PWV) in a cohort of FH subjects. Methods In this prospective observational study, we evaluated 56 FH subjects on high-intensity statins plus ezetimibe and with an off-target LDL-C. All subjects were placed on PCSK9-i therapy and obtained biochemical analysis as well as PWV evaluation at baseline and after six months of PCSK9-i therapy. Results After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets. As expected, a significant reduction of LDL-C (- 49.61%, p < 0.001) was observed after PCSK9-i therapy. Neutrophil count (NC) and MHR were reduced by PCSK9-i (-13.82% and -10.47%, respectively, p value for both < 0.05) and PWV significantly decreased after PCSK9-i therapy (- 20.4%, p < 0.05). Finally, simple regression analyses showed that increment PWV was significantly associated with increment LDL-C (p < 0.01), increment NC and increment MHR (p value for both < 0.05). Conclusions In conclusion, PCSK9-i therapy significantly improved lipid and inflammatory profiles and PWV values in FH subjects; our results support the positive effect of PCSK9-i in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available